FDA grants fast track status to MedImmune’s MEDI3902 for prevention of P. aeruginosa
P. aeruginosa is a highly drug-resistant bacterial pathogen that causes serious disease in hospitalized patients. MEDI3902 is a new mAb engineered to combine three distinct mechanisms of action
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.